MHRA Publishes Strategy 2030 for an AI-Era Regulator

MHRA published its Strategy 2030 on October 14, closing a loop the agency opened in its own annual report two months earlier. Where that August document flagged a forthcoming strategy in a single forward-looking line, Strategy 2030 is the actual framework: an AI-enabled trial-protocol checker, a target to halve scientific-advice timelines, and an explicit bet that the UK's regulatory advantage over the next four years rests on how fast it can move on artificial intelligence and personalised medicine.

What the strategy actually commits to

Strategy 2030 sets three priority areas — advanced therapies, personalised medicine and artificial intelligence — and attaches concrete tools to each. The AI-enabled clinical trial protocol checker is the most immediately actionable item for sponsors: a tool meant to screen trial-protocol submissions before or during MHRA's own review, aimed at catching the kind of protocol-design issues that currently surface as review-cycle delays. The AI Medicines Development Action Plan, which MHRA says it will publish next year, is the broader policy vehicle; the strategy document does not yet specify what that plan will contain beyond signaling that AI-assisted drug development — not just AI as a medical device category MHRA already regulates — is now an explicit strategic priority rather than something the agency addresses only through existing software and SaMD guidance.

The timeline commitments, and one unresolved detail

On review speed, the strategy restates MHRA's commitment to a 14-day first assessment for qualifying Phase 1 clinical trial applications under the UK's new Clinical Trials Regulations — a target MHRA's 2025-26 annual report, published in August, had already flagged as arriving this year, with a stepwise rollout due by the end of 2026. Strategy 2030's contribution is confirming that commitment sits inside the broader 2030 framework rather than retracting or softening it. The newer figure is a target to cut scientific-advice review timelines from 90 days to 45 — but trade coverage is not fully consistent about which service it applies to. RAPS's reporting frames it as a fast-track scientific-advice offering specifically; Pharmaceutical Technology's coverage describes it as the general scientific advice service for both drug and device developers. MHRA's own published service guarantees for standard Scientific Opinions, in the industry explainer document accompanying the strategy, still list a 90-day figure. Regulatory News was not able to reconcile that discrepancy from secondary sources alone; sponsors relying on the 45-day figure for planning should confirm the exact scope against MHRA's full strategy text rather than either summary.

Why this lands differently than a typical strategy refresh

• MHRA pledges closer working with NICE, aimed at aligning regulatory approval and health-technology assessment timelines rather than treating them as sequential, independent processes.
• The strategy's AI focus extends beyond devices: it signals MHRA intends to shape how AI-assisted drug discovery and development data gets evaluated, not only how AI-as-a-medical-device products get classified and cleared.
• Industry's first public reaction, via the ABPI, was positive — though trade associations typically welcome regulatory speed commitments before implementation detail arrives.
• The strategy sets direction and targets through 2030; it is not itself a binding rule change, and several of its headline figures (the protocol checker, the AI Medicines Development Action Plan) are tools and plans still to be built, not services available today.

For sponsors planning UK submissions, the practical takeaway is to treat the 14-day Phase 1 target as the most concrete, already-telegraphed commitment to plan around, and to treat the 45-day scientific-advice figure and the AI tooling as directional until MHRA publishes the implementation detail — the Action Plan next year, and whatever rulemaking or guidance follows the protocol-checker pilot.

Frequently asked questions

What is Strategy 2030, and when was it published?

MHRA Strategy 2030 is the UK Medicines and Healthcare products Regulatory Agency's published strategic framework for how it will regulate medicines and devices through 2030, with an explicit focus on keeping pace with artificial intelligence and personalised medicine. MHRA and the UK government published it on 14 October 2026.

What is actually new in this document?

The headline new commitments are an AI-enabled clinical trial protocol checker, an AI Medicines Development Action Plan MHRA says it will publish next year, a target to cut scientific-advice review timelines from 90 to 45 days, and a pledge to work more closely with NICE. The strategy also restates a 14-day first-assessment target for qualifying Phase 1 clinical trial applications that MHRA's 2025-26 annual report first flagged as coming in August 2026 — that figure is a confirmation and operational detail, not new news on its own.

Does the 45-day scientific-advice target apply to every advice request?

Trade press is not fully consistent on scope. RAPS describes the reduction from 90 to 45 days as applying to fast-track scientific advice specifically, while Pharmaceutical Technology describes it as covering the general scientific advice service for drug and medical device developers. MHRA's own published service guarantees for standard Scientific Opinions still list 90 days. Regulatory News has not been able to reconcile the exact scope from secondary coverage alone and recommends checking MHRA's full strategy document or industry explainer for the precise commitment before relying on either figure.

How has industry responded?

The Association of the British Pharmaceutical Industry (ABPI) welcomed the strategy, according to trade coverage of its publication. MHRA says the strategy's priority areas are advanced therapies, personalised medicine and AI.